<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04185545</url>
  </required_header>
  <id_info>
    <org_study_id>RV 0319</org_study_id>
    <nct_id>NCT04185545</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Rotavirus RV3 Vaccine (Bio Farma) in Neonates</brief_title>
  <official_title>Immunogenicity and Safety of Rotavirus RV3 Vaccine (Bio Farma) in Neonates, Lot to Lot Consistency and Antigen Interference With Co-Administered EPI Vaccines (Phase III)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT Bio Farma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PT Bio Farma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase III trial aims to assess the immunogenicity and safety of Rotavirus RV3 Vaccine
      (Bio Farma) in neonates, lot-to-lot consistency, and antigen interference with
      co-administered EPI vaccines
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blind, placebo-controlled, six-arm parallel-group study to
      investigate the safety and immunogenicity following three doses of rotavirus RV3 vaccine (Bio
      Farma) administered as a neonatal schedule
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum immune response (sIgA) following third dose</measure>
    <time_frame>28 days after the third dose</time_frame>
    <description>Percentage of subjects with ≥ 3 times increase in serum anti-rotavirus IgA (sIgA) from baseline to 28 days after the third dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum anti-rotavirus IgA (sIgA) following third dose</measure>
    <time_frame>28 days after the third dose</time_frame>
    <description>Percentage of subjects with ≥ 3 times increase in serum anti-rotavirus IgA (sIgA) from baseline to 28 days after the third dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum anti-rotavirus IgA (sIgA) following second dose</measure>
    <time_frame>28 days after the second dose</time_frame>
    <description>Percentage of subjects with ≥ 3 times increase in serum anti-rotavirus IgA (sIgA) from baseline to 28 days after the second dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum anti-rotavirus IgA (sIgA) following first dose</measure>
    <time_frame>28 days after the first dose</time_frame>
    <description>Percentage of subjects with ≥ 3 times increase in serum anti-rotavirus IgA (sIgA) from baseline to 28 days after the first dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum neutralizing antibodies (SNA) following third dose</measure>
    <time_frame>28 days after the third dose</time_frame>
    <description>Description of serum neutralising antibodies (SNA) level [percentage of subjects with positive SNA(≥ 100), two fold and three fold increasing antibodies] from baseline to 28 days after the third dose [in a subset of 80 participants per arm]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titre (GMT) following third dose</measure>
    <time_frame>28 days after the third dose</time_frame>
    <description>Geometric mean titre (GMT) of serum IgA and serum neutralising antibodies (SNA) 28 days after the third dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool excretion following each dose</measure>
    <time_frame>3-5 days after each dose</time_frame>
    <description>Detectable RV3 excretion in stool (by PCR) any day from day 3 to day 5 following each dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine take</measure>
    <time_frame>28 days after each dose</time_frame>
    <description>At least a threefold increase in serum anti-rotavirus IgA or SNA from baseline to post rotavirus vaccine dosing, or detectable RV3 excretion in stool (by PCR) any day from day 3 to day 5 following each dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative vaccine take</measure>
    <time_frame>28 days after the third dose</time_frame>
    <description>Vaccine take observed at the current assessment time point or following any previous dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lot to lot consistency</measure>
    <time_frame>28 days after the third dose</time_frame>
    <description>Percentage of subjects with ≥ 3 times increase in serum anti-rotavirus IgA (sIgA) from baseline to 28 days after the third dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotective response</measure>
    <time_frame>28 days after non-EPI vaccination</time_frame>
    <description>Reciprocal titre ≥ 1:8 against poliovirus strains 1-3 measured 28 days after bOPV4+ IPV and Pentabio 3 vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited and unsolicited adverse events (AE)</measure>
    <time_frame>Up to 28 days after the third dose</time_frame>
    <description>Number of solicited and unsolicited Adverse Events (AE), from randomization to 28 days following last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events (SAE)</measure>
    <time_frame>Up to 28 days after the third dose</time_frame>
    <description>Number of Serious Adverse Events (SAE), from randomization to 28 days following last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE and SAE compared to placebo</measure>
    <time_frame>Up to 28 days after the third dose</time_frame>
    <description>Number of Adverse Events and Serious Adverse Events (SAE), from randomization to 28 days following last dose, compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormality of ALT and AST levels</measure>
    <time_frame>28 days after the first dose</time_frame>
    <description>Abnormality of ALT and AST levels measured 28 days following first dose, assessed as probably or definitely related to the dosing</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Rotavirus Gastroenteritis</condition>
  <arm_group>
    <arm_group_label>Main Study I - RV3 Vaccine (Bio Farma) Batch 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 oral doses of RV3 vaccine (Bio Farma) batch 1; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Main Study I - RV3 Vaccine (Bio Farma) Batch 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 oral doses of RV3 vaccine (Bio Farma) batch 2; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Main Study I - RV3 Vaccine (Bio Farma) Batch 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 oral doses of RV3 vaccine (Bio Farma) batch 3; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Main Study I - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 oral doses of Placebo; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Main Study II - RV3 Vaccine (Bio Farma)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 oral doses of RV3 vaccine (Bio Farma) with the addition of antacid prior to dose 2 and 3; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Main Study II - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 oral doses of Placebo with the addition of antacid prior to dose 2 and 3; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rotavirus RV3 Vaccine (Bio Farma)</intervention_name>
    <description>Each 1 mL dose of the final product of oral liquid rotavirus vaccine contains &gt; 5x10^6 fcfu/mL rotavirus vaccine strain RV3</description>
    <arm_group_label>Main Study I - RV3 Vaccine (Bio Farma) Batch 1</arm_group_label>
    <arm_group_label>Main Study I - RV3 Vaccine (Bio Farma) Batch 2</arm_group_label>
    <arm_group_label>Main Study I - RV3 Vaccine (Bio Farma) Batch 3</arm_group_label>
    <arm_group_label>Main Study II - RV3 Vaccine (Bio Farma)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Each 1 mL dose of placebo contains 30% of sucrose in DMEM</description>
    <arm_group_label>Main Study I - Placebo</arm_group_label>
    <arm_group_label>Main Study II - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Neonate 0-5 days (0-144 hours) of age at the time of first dose.

          2. Neonate is in good health as determined by clinical judgment, including a medical
             history and physical exam, which confirms the absence of a current or past disease
             state considered significant by the investigator.

          3. The neonate was born full term (minimum of 37 completed weeks and maximum of 42
             completed weeks gestation).

          4. Neonate birth weight 2500-4000 g inclusive.

          5. Parent or guardian has been informed properly regarding the study and signed the
             informed consent form.

          6. Parent or guardian commits to comply with the instructions of the investigator and the
             schedule of the trial.

        Exclusion Criteria:

          1. Subject concomitantly enrolled or scheduled to be enrolled in another trial.

          2. The subject has direct relatives relationship with the study team.

          3. The subject has evolving mild, moderate or severe illness, especially infectious
             diseases or fever (axillary temperature ³ 37.5°C) within the 48 hours preceding
             enrollment.

          4. Subject with a known or suspected history of allergy to any component of the vaccines
             (based on anamnesis).

          5. Subject with a biological mother with a known or suspected human immunodeficiency
             virus (HIV) infection.

          6. Subject with known or suspected major congenital malformations or genetically
             determined disease.

          7. Subject with intussusception.

          8. Subject with a known or suspected disease of uncontrolled coagulopathy or blood
             disorders contraindicating for phlebotomy.

          9. Subject with a known or suspected disease of the immune system or those who have
             received immunosuppressive therapy, including immunosuppressive courses of systemic
             corticosteroid.

         10. Subject who have ever received any blood products, including immunoglobulin, or for
             whom receipt of any blood product is anticipated during the course of study.

         11. Any abnormality or chronic disease which according to the investigator might interfere
             with the assessment of the trial objectives.

         12. Subject immunized with non-EPI vaccines.

         13. Gastroenteritis in the 24 hours preceding dosing (temporary exclusion criteria).

         14. Subject planning to move from the study area before the end of the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jarir At Thobari</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Research Office (PRO), Faculty of Medicine Universitas Gadjah Mada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novilia Sjafri Bachtiar</last_name>
    <phone>+6222-2033755</phone>
    <phone_ext>14101</phone_ext>
    <email>novilia@biofarma.co.id</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dr. Moewardi District Hospital</name>
      <address>
        <city>Surakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gajahan Primary Health Center</name>
      <address>
        <city>Surakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gambirsari Primary Health Center</name>
      <address>
        <city>Surakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pajang Primary Health Center</name>
      <address>
        <city>Surakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sangkrah Primary Health Center</name>
      <address>
        <city>Surakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sibela Primary Health Center</name>
      <address>
        <city>Surakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayat Primary Health Center</name>
      <address>
        <city>Yogyakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>dr. Soeradji Tirtonegoro General Hospital</name>
      <address>
        <city>Yogyakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gantiwarno Primary Health Center</name>
      <address>
        <city>Yogyakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jogonalan 1 Primary Health Center</name>
      <address>
        <city>Yogyakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jogonalan 2 Primary Health Center</name>
      <address>
        <city>Yogyakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karanganom Primary Health Center</name>
      <address>
        <city>Yogyakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kebonarum Primary Health Center</name>
      <address>
        <city>Yogyakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kebondalem Lor Primary Health Center</name>
      <address>
        <city>Yogyakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klaten Selatan Primary Health Center</name>
      <address>
        <city>Yogyakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ngawen Primary Health Center</name>
      <address>
        <city>Yogyakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pedan Primary Health Center</name>
      <address>
        <city>Yogyakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prambanan Primary Health Center</name>
      <address>
        <city>Yogyakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trucuk 1 Primary Health Center</name>
      <address>
        <city>Yogyakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trucuk 2 Primary Health Center</name>
      <address>
        <city>Yogyakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wedi Primary Health Center</name>
      <address>
        <city>Yogyakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 27, 2019</study_first_submitted>
  <study_first_submitted_qc>December 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroenteritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

